A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

NCT04049929 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: YY-20394

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.